What is Xcell Biosciences?
Xcellbio is a venture-backed entity dedicated to enhancing the performance and safety of cell and gene-based therapies. The company designs and develops pioneering technology platforms, including commercial instruments and AI-driven software. These tools empower researchers to uncover novel insights into immune and tumor biology, facilitating the translation of these discoveries at a patient scale through its advanced cell therapy manufacturing platform. The company's mission is to revolutionize the therapeutic landscape by providing cutting-edge solutions for complex biological challenges.
How much funding has Xcell Biosciences raised?
Xcell Biosciences has raised a total of $39.7M across 3 funding rounds:
Series A
$12M
Debt
$240K
Series B
$27.5M
Series A (2017): $12M with participation from Viking Global Investors
Debt (2021): $240K led by PPP
Series B (2022): $27.5M supported by Viking Global Investors, Dynamk Capital, Labcorp, and Casdin Capital
Key Investors in Xcell Biosciences
Viking Global Investors
Viking Global Investors is a global investment firm specializing in research-intensive, long-term focused investments using fundamental analysis to select public and private equity interests across industries and geographies.
Dynamk Capital
Dynamk Capital is a New York-based venture capital firm that specializes in investing in life science industrials, focusing on tools, technologies, and services essential for the discovery, development, and production of life-saving therapies.
Labcorp
Labcorp Holdings Inc. operates as a laboratory services company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions.
What's next for Xcell Biosciences?
With the recent influx of major strategic investment, Xcell Biosciences is poised for accelerated growth and innovation. The enterprise-level capital infusion is expected to fuel the expansion of its technology platforms, enhance its AI-driven software capabilities, and broaden its market reach within the rapidly evolving cell and gene therapy sector. This strategic backing will likely enable Xcell Biosciences to further its mission of improving cell therapy manufacturing and translating critical research insights into scalable patient treatments, positioning the company as a leader in the biotech industry.
See full Xcell Biosciences company page
